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associated with systemic sclerosis: a
randomized, controlled, double-blind,
parallel group study (EDITA study)
Zixuan Pan1,2†, Alberto M. Marra3†, Nicola Benjamin1,2, Christina A. Eichstaedt1,2,4, Norbert Blank5,
Eduardo Bossone6, Antonio Cittadini7, Gerry Coghlan8, Christopher P. Denton9, Oliver Distler10,
Benjamin Egenlauf1,2, Christine Fischer4, Satenik Harutyunova1,2, Panagiota Xanthouli1,2, Hanns-Martin Lorenz and
Ekkehard Grünig1,2*
Abstract
Objective: The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the
effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and
mildly elevated pulmonary hypertension (PH).
Methods: Thirty-eight SSc patients with mildly elevated mPAP at rest between 21 and 24 mmHg and/or > 30
mmHg during low-dose exercise were randomly assigned to treatment with either ambrisentan 5–10 mg/day or
placebo. Right heart catheterization and further clinical parameters were assessed at baseline and after 6 months.
The primary endpoint was the difference of mPAP change at rest between groups.
Results: After 6 months, the two groups did not differ in the primary endpoint (ambrisentan mPAP − 1 ± 6.4 mmHg
vs. placebo − 0.73 ± 3.59 mmHg at rest, p = 0.884). However, three patients from the placebo group but none of the
ambrisentan group progressed to SSc-associated pulmonary arterial hypertension. Furthermore, ambrisentan
treatment showed significant improvements in the secondary endpoints cardiac index (CI) and pulmonary vascular
resistance (PVR) at rest (CI 0.36 ± 0.66 l/min/m2 vs. − 0.31 ± 0.71 l/min/m2, p = 0.010; PVR − 0.70 ± 0.78 WU vs. 0.01 ±
0.71 WU, p = 0.012) and during exercise (CI 0.7 ± 0.81 l/min/m2 vs. − 0.45 ± 1.36 l/min/m2, p = 0.015; PVR − 0.84 ±
0.48 WU vs. − 0.0032 ± 0.34 WU, p < 0.0001).
Conclusion: This is the first randomized, double-blind, placebo-controlled study testing the effect of ambrisentan in
patients with mildly elevated mPAP and/or exercise PH. The primary endpoint change in mPAP did only
tendentially improve in the ambrisentan group, but the significant improvement of other hemodynamic parameters
points to a possible benefit of ambrisentan and will be helpful to design future trials.
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Background
Pulmonary hypertension (PH) is a manifestation of sys-
temic sclerosis (SSc) [1] which dramatically impairs pa-
tients’ prognosis [2]. In the American REVEAL registry,
patients with SSc-associated-pulmonary arterial hyper-
tension (PAH) (SSc-APAH) had the worst 1-, 2-, and 3-
year survival rates of 78, 58, and 47%, respectively [3]. If
left untreated, SSc-APAH patients have a median sur-
vival rate of 1 year after diagnosis [4]. Mildly elevated
mean pulmonary arterial pressure (mPAP) of 21–24
mmHg has been shown to be associated with impaired
exercise capacity and poorer outcomes when compared
with individuals with mPAP within the normal range
[5–7, 38]. A recently published post hoc analysis of the
DETECT study showed that SSc patients with mPAP of
21–24mmHg were also more prone to develop manifest
PH after 2.95 ± 0.7 years follow-up (chi-square p value
0.0226) than SSc patients with mPAP of ≤ 20mmHg [8].
In a recent study, patients with SSc and mildly elevated
mPAP presented with impaired pulmonary arterial com-
pliance and reduced increase of cardiac index (CI)
assessed by right heart catheterization (RHC) during ex-
ercise [9]. During the 6th World Symposium on Pulmon-
ary Hypertension, a new definition of PH has been
proposed, lowering the cutoff for mPAP from ≥ 25 to >
20mmHg and including the criterion of a pulmonary
vascular resistance (PVR) > 3 Wood Units for all forms
of precapillary PH [10]. This new definition may allow
an earlier identification of PH in SSc patients.
Ambrisentan is an endothelin receptor antagonist with
endothelin receptor A selectivity, which was developed
for the targeted treatment of PAH. Ambrisentan was
evaluated in two large phase III randomized controlled
trials in ARIES (ambrisentan in pulmonary arterial
hypertension, randomized, double-blind, placebo-con-
trolled, multicenter, efficacy study)-1 and ARIES-2 for
the treatment of PAH [11]. In both studies, ambrisentan
has demonstrated beneficial effects on PAH symptoms,
exercise capacity, hemodynamics, and time to clinical
worsening, defined as occurrence of death, lung trans-
plantation, atrial septostomy, and study withdrawal be-
cause of addition of other PAH medication or “early
escape” criteria (the occurrence of two of the following:
> 20% decrease of a 6-min walking distance (6MWD),
increase in the World Health Organization functional
class (WHO-FC), worsening right ventricular function,
hepatic or renal failure, systolic blood pressure < 85
mmHg). In PAH patients, mPAP improved about 15%
due to ambrisentan [12]. Due to its beneficial effects on
the development of digital ulcerations in patients with
SSc [13, 14], the endothelin receptor antagonist bosen-
tan has been approved for the treatment of digital
ulcers.
Up to now, apart from two small, uncontrolled open-
label reports [15, 16], data regarding the treatment of
mildly elevated mPAP and/or exercise PH is lacking. As
an early recognition and management of PAH in SSc
grants a significant survival benefit [17], there is a high
need of randomized, controlled studies investigating the
effect of PAH-targeted treatment in SSc patients with
mildly elevated mPAP and/or exercise PH. As ambrisen-
tan seems to have a better safety profile than the
endothelin receptor antagonist bosentan with regard to
hepatic safety and drug-drug interactions [18], we aimed
to investigate the effect of ambrisentan on patients with
SSc and mildly elevated mPAP and/or exercise PH.
The aim of this study was therefore to investigate,
whether an early treatment in patients with mildly
elevated mPAP and/or exercise PH may prevent these
patients from worsening of hemodynamics. Mean PAP
has been chosen as a primary endpoint in order to de-
tect the progression to manifest PH.
Material and methods
Study subjects
Patients affected by diffuse cutaneous SSc (dcSSc) and
limited cutaneous SSc (lcSSc) [19] referred to our center
for the purpose of PH screening which was performed
according to a modified DETECT algorithm were
enrolled into the study [20]. All SSc patients received a
complete non-invasive clinical assessment including
echocardiography at rest and right heart catheterization
at rest and during exercise. The patients were enrolled
in this study if they had either (1) resting mPAP 21–24
mmHg, pulmonary arterial wedge pressure (PAWP) <
15mmHg, transpulmonary gradient (TPG =mPAP-
PAWP) > 11mmHg, or (2) exercise-induced elevated
mPAP values > 30mmHg, PAWP < 18mmHg, and TPG
> 15mmHg which occurred at low workloads (cardiac
output (CO) < 10 l/min) [21] without significant left
heart or severe lung disease. Inclusion of patients was
based on pulmonary pressures and not on PVR, as this
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criterion [10] was not yet implemented during the
conduct of the study. Left heart disease was assessed by
clinical examinations including electrocardiogram
(ECG), echocardiography, stress echocardiography, stress
ECG, and laboratory testing of the N-terminal fraction
of the pro-brain natriuretic peptide and troponin T
(NTproBNP, TnT ≥ 14). In the case of suspected coron-
ary artery disease or any other left heart disease in pa-
tients with elevated wedge pressures, patients were
referred for left heart catheterization. Lung diseases were
assessed by lung function tests, by chest X-ray, and if
clinically indicated by high-resolution computed tomog-
raphy (HRCT). Lung involvement of SSc was considered
significant when forced vital capacity (FVC) was < 60%,
or HRCT showed severe fibrosis, or when FVC was 60–
70% and HRCT showed moderate-severe fibrosis or was
“not available,” as previously described [20]. Diagnosis of
SSc was confirmed by experienced rheumatologists
(HML, NoB) according to the standard criteria of the
American Rheumatism Association [22] with a SSc dis-
ease duration from first non-Raynaud symptoms > 3
years. Manifest PH/PAH was diagnosed according to the
current ERS/ESC guidelines [23].
A written informed consent was obtained from all pa-
tients in accordance with the Declaration of Helsinki. The
approval of the ethics committee of the Medical Faculty
Heidelberg was obtained (AFmo-407/2014); the trial was
registered on www.ClinicalTrials.gov (unique identifier
NCT: NCT02290613) and in the European Clinical Trial
Register (EudraCT Number: 2014-001882-28).
Study design
The EDITA study was a single-center (PH Center, Thor-
axklinik at Heidelberg University Hospital, Heidelberg,
Germany) investigator-initiated trial using a prospective,
randomized, double-blind (patient and investigator),
parallel group, placebo-controlled, phase IIA clinical
study design. Patients were randomized 1:1 to either
ambrisentan or placebo by simple randomization.
Medication was prepared at the Department of Medical
Pharmacy, University of Heidelberg, according to the al-
location order and labeled with the patient numbers.
Treatment allocation was concealed until database clos-
ure. Ambrisentan treatment was started at a dose of 5
mg/day and uptitrated to 10mg/day after 1–4 weeks ac-
cording to tolerability. Placebo tablets with the same
color and shape as ambrisentan were provided by Glax-
oSmithKline. Patients were assessed at baseline, after 3
and 6months including medical history, demographics,
concomitant medication, physical examination, WHO-
FC, vital signs, SSc characteristics, 12-lead ECG, 6MWD
including Borg dyspnea score, 2-dimensional-echocardi-
ography at rest, clinical laboratory including pregnancy
test, lung function test with blood gas analysis, and
monitoring of adverse events. Modified Rodnan skin
score (mRSS), echocardiography, RHC with continuous
3-lead ECG at rest and during exercise, and quality of
life (QoL) questionnaire (short form health survey SF-
36) were performed at baseline and after 6 months only.
An appropriate contraception throughout the study was
required for women with child-bearing potential.
Endpoints
The primary endpoint was the change from baseline to
6 months in resting mPAP with ambrisentan compared
to change with placebo.
Secondary endpoints included changes from baseline to
6months in further invasively measured hemodynamic
parameters at rest and during exercise (RHC: right atrial
pressure, PVR, CO, cardiac index (CI), PAWP, venous
oxygen saturation (SvO2)), WHO-FC, mRSS and symp-
toms of SSc (presence of (digital) ulcers, calcinosis, dys-
phagia, telangiectasia, Raynaud phenomenon, and joint
pain), 6MWD, QoL (SF-36), lung function tests, right
heart dimensions and function assessed with transthoracic
echocardiography, and NTproBNP. Measures of disease-
related progression (adverse events, hospitalization, and
initiation of PAH treatment) and the assessment of toler-
ability and safety were assessed throughout the study and
during the safety follow-up period.
Study procedures
The hemodynamic values were obtained by RHC. The
RHC was performed in a standardized way in a supine
position using the transjugular access with a triple-
lumen 7F-Swan-Ganz thermodilution catheter at rest
and during exercise as previously described [9]. Resting
two-dimensional transthoracic echocardiography Dop-
pler examinations were performed by experienced
cardiac sonographers (EG, AMM, SH) with commer-
cially available equipment (Vivid 9, GE Healthcare,
Milwaukee, WI) according to a standardized protocol as
described previously [24].
Statistical analysis
Statistical analyses were conducted by two statisticians
(CF, NB). Data are described as mean ± standard devi-
ation (SD) and 95% confidence interval or number and
%, respectively.
Based on data from the literature [16], we calculated
that 15 patients (18 including a 20% dropout rate) would
have 90% power to detect a placebo-corrected mean dif-
ference of mPAP (baseline to 6months) of 3 ± 2.5 mmHg
(equal standard deviation) at a two-sided significance
level of 0.05. The primary efficacy analysis was per-
formed on data from the intention-to-treat population
(all patients who received randomization) by a t-test
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with unequal variances (Welch tests) since the assump-
tion for a covariance analysis was not fulfilled.
Secondary hemodynamic endpoints were tested with t-
tests for unequal variances. Safety was analyzed descrip-
tively. Adverse events during the study period included
all adverse events that started or worsened at the time of
administration of the first dose of study drug until the
last visit (6 months).
Total pulmonary resistance (TPR) was calculated as
mPAP-CO slope using the formula TPR =mPAP at peak
exercise/CO at peak exercise [21]. All tests were two-
tailed, and p values < 0.05 were considered as statistically
significant. Secondary endpoints were tested exploratory.
As sensitivity analysis, changes in WHO-FC, 6-min
walking test, QoL, and skin fibrosis were analyzed in pa-
tients with dcSSc only. All analyses were performed with
SPSS V25 (SPSS Statistics V25, IBM Corporation,
Somers, NY) and JMP14 (SAS Institute, Cary, NC).
Results
In this study, 38 SSc patients were randomly assigned to
receive placebo or ambrisentan (5–10mg/day) in the
EDITA study from December 2014 until April 2017. Of
these, 32 patients completed the study (15 in the placebo
group and 17 in the ambrisentan group, Fig. 1): 78.9%
female, mean age 56.8 ± 11.0 years, 39.5% dcSSc, 60.5%
lcSSc. All of the 38 patients had already symptoms such
as shortness of breath during exercise. Baseline parame-
ters were well balanced between the two groups
(Table 1), except for SSc subtype and duration of SSc.
Hemodynamics at rest and during exercise
The primary endpoint, mean change of resting mPAP,
was not significantly different between ambrisentan and
placebo (p = 0.884, Table 2, Fig. 2). After 6 months,
mPAP at peak exercise increased with placebo, whereas
it decreased with ambrisentan, though not significantly
different (p = 0.494).
After 6 months, 5 patients presented with resting
mPAP values above ≥ 25mmHg (placebo n = 3, ambri-
sentan n = 2). The 3 patients of the placebo group were
classified as manifest PAH. They were aged 25, 55, and
56 years respectively, had a resting PAWP of ≤15 mmHg
both at rest and during exercise at month 6, and had
shortness of breath. Their mPAP values were 24 mmHg
at baseline and increased within 6 months to values ≥ 25
mmHg. In all 3 PAH patients, the disease was diagnosed
at a very early stage (27 ± 3.5 mmHg), and in 2 patients,
the increase of mPAP was only very mild (Fig. 2) most
likely due to the short observation period. Up-front
targeted PAH medication was started in these patients
immediately after the second RHC was performed and
the end of the study was reached.
Fig. 1 Study flowchart. A total of 38 patients were enrolled into our study and randomly assigned to be treated with ambrisentan 5 or 10 mg/
day or to receive placebo. After 6 months, 32 patients completed the study, 17 in the ambrisentan group, and 15 in the placebo group. Among
the 6 dropout patients, 1 in the ambrisentan group and 2 in the placebo group withdrew their written informed consents. One in each group
quit because of adverse events, one in the ambrisentan group for gingival bleeding, and one in the placebo group for angina pectoris. One
patient in the placebo group was lost to follow-up
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Table 1 Demographic and clinical characteristics of the study population
Parameter [unit] Placebo
(N = 19)
Ambrisentan
(N = 19)
Total
(N = 38)
Mean ± SD 95% CI n Mean ± SD 95% CI n 95% CI of
difference
Mean ± SD 95% CI n
Female sex no. [%] 14 (73.7) 16 (84.2) 30 (78.9)
Age [years] 54.89 ±
11.23
(49.48 to
60.31)
58.79 ±
10.75
(53.61 to
63.97)
(− 3.33 to
11.12)
56.84 ±
11.02
(53.22 to
60.46)
Height [cm] 166.21 ±
10.19
(161.30 to
171.12)
166.05 ±
5.59
(163.36 to
168.75)
(− 5.62 to
5.31)
166.13 ±
8.11
(163.47 to
168.80)
Weight [kg] 74.81 ±
17.25
(66.48 to
83.10)
71.45 ±
15.83
(64.03 to
79.22)
(− 14.03 to
7.70)
73.13 ±
16.42
(67.83 to
78.59)
Systolic blood pressure [mmHg] 121.32 ±
14.99
(114.09 to
128.54)
116.32 ±
11.53
(110.76 to
121.87)
(− 13.80 to
3.80)
118.82 ±
13.43
(114.40 to
123.23)
Diastolic blood pressure [mmHg] 73.42 ± 9.14 (69.02 to
77.82)
73.68 ± 8.95 (69.37 to
78.00)
(− 5.69 to
6.21)
73.55 ± 8.92 (70.62 to
76.49)
HR [beats/min] 77.58 ± 9.85 (72.83 to
82.33)
73.05 ±
11.12
(67.69 to
78.41)
(− 11.44 to
2.39)
75.32 ±
10.61
(72.83 to
78.81)
WHO-FC no. [%]
II 15 (78.9) 17 (89.5) 32 (84.2)
III 4 (21.1) 2 (10.5) 6 (15.8)
Hemodynamic characteristic according to inclusion criteria
mPAP rest 21–24 mmHg, mPAP
exercise > 30 mmHg
12 (63.2) 10 (52.6) 22 (57.9)
mPAP rest 21–24 mmHg, mPAP
exercise ≤ 30 mmHg
3 (15.8) 1 (5.3) 4 (10.5)
mPAP rest < 21 mmHg, mPAP
exercise > 30 mmHg
4 (21.0) 8 (42.1) 2 (31.6)
mRSS [points] 11.47 ± 5.22 (8.72 to
14.23)
11.47 ± 5.71 (8.96 to
13.99)
(− 3.60 to
3.60)
11.47 ± 5.40 (9.70 to
13.25)
SSc subgroup, no. (%)
Diffuse 11 (57.9) 4 (21.1) 15 (39.5)
Limited 8 (42.1) 15 (78.9) 23 (60.5)
SSc disease duration [years] 13.28 ±
10.85
(8.05 to
18.51)
6.63 ± 4.80 (4.32 to 8.96) (− 12.17 to
1.12)
9.96 ± 8.93 (7.02 to
12.90)
Hemodynamics at rest
CVP [mmHg] 5.63 ± 2.97 (4.20 to 7.06) 6.11 ± 2.94 (4.69 to 7.52) (− 1.47 to
2.41)
5.87 ± 2.92 (4.90 to 6.82)
mPAP [mmHg] 21.32 ± 2.43 (20.15
to22.49)
19.84 ± 3.58 (18.12 to
21.57)
(− 3.49 to
0.54)
20.58 ± 3.11 (19.56 to
21.60)
PAWP [mmHg] 9.58 ± 2.97 (8.15 to
11.01)
9.42 ± 2.32 (8.30 to
10.54)
(− 1.91 to
1.59)
9.50 ± 2.63 (8.64 to
10.37)
CO [l/min] 5.66 ± 1.48 (4.95 to 6.37) 5.04 ± 1.26 (4.43 to 5.65) (− 1.51 to
0.29)
5.35 ± 1.39 (4.89 to 5.81)
CI [l/min/m2] 3.20 ± 0.85 (2.79 to 3.61) 2.84 ± 0.64 (2.53 to 3.14) (− 0.86 to
0.13)
3.02 ± 0.76 (2.77 to 3.27)
SvO2 [%] 73.13 ± 4.60 (70.67 to
75.58)
(16) 73.91 ± 8.58 (69.50 to
78.32)
(17) (− 4.15 to
5.71)
73.53 ± 6.85 (71.10 to
75.96)
(33)
PVR [WU] 2.09 ± 0.61 (1.80 to 2.39) 2.22 ± 0.93 (1.77 to 2.67) (− 0.39 to
0.65)
2.16 ± 0.78 (1.90 to 2.41)
Hemodynamics at peak exercise
mPAP [mmHg] 36.94 ± 6.08 (33.82 to
40.07)
(17) 37.78 ± 3.61 (35.98 to
39.57)
(18) (− 2.58 to
2.25)
37.37 ± 4.91 (35.69 to
39.06)
(35)
PAWP [mmHg] 15.24 ± 5.43 (12.45 to
18.03)
(17) 16.78 ± 6.42 (13.58 to
19.97)
(18) (− 2.56 to
5.64)
16.03 ± 5.92 (13.99 to
18.06)
(35)
CO [l/min] 11.03 ± 3.62 (9.17 to (17) 9.67 ± 2.67 (8.34 to (18) (− 3.54 to 10.33 ± 3.19 (9.23 to (35)
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Table 1 Demographic and clinical characteristics of the study population (Continued)
Parameter [unit] Placebo
(N = 19)
Ambrisentan
(N = 19)
Total
(N = 38)
Mean ± SD 95% CI n Mean ± SD 95% CI n 95% CI of
difference
Mean ± SD 95% CI n
12.89) 10.99) 0.81) 11.43)
CI [l/min/m2] 6.04 ± 1.79 (5.12 to 6.96) (17) 5.41 ± 1.32 (4.75 to 6.06) (18) (− 1.71 to
0.45)
5.71 ± 1.58 (5.17 to 6.25) (35)
SvO2 [%] 38.27 ± 6.10 (34.89 to
41.64)
(15) 42.77 ±
11.56
(36.36 to
49.17)
(15) (− 2.42 to
11.42)
40.52 ± 9.37 (37.02 to
44.02)
(30)
Workload [Watt] 75.00 ±
34.23
(57.40 to
92.60)
(17) 75.00 ±
27.12
(61.52 to
88.48)
(18) (− 21.18 to
21.17)
75.00 ±
30.32
(65.59 to
85.41)
(35)
HR max [/min] 117.65 ±
21.37
(106.66 to
128.63)
(17) 111.39 ±
23.06
(99.92 to
122.86)
(18) (− 21.57 to
9.06)
114.43 ±
22.15
(106.82 to
122.04)
(35)
PVR [WU] 2.07 ± 0.61 (1.76 to 2.38) (17) 2.29 ± 0.85 (1.87 to 2.71) (18) (− 0.29 to
0.73)
2.18 ± 0.74 (1.93 to 2.44) (35)
TPR [mmHg min l− 1] 3.65 ± 1.18 (3.04 to 4.26) (17) 4.28 ± 1.65 (3.46 to 5.10) (18) (− 0.36 to
1.62)
3.97 ± 1.46 (3.47 to 4.47) (35)
6MWD
6MWD [m] 448.11 ±
82.64
(408.28 to
487.93)
470.21 ±
77.03
(433.08 to
407.34)
(− 30.46 to
74.67)
459.16 ±
79.59
(433.00 to
485.32)
Borg dyspnea score 2.93 ± 1.97 (1.98 to 3.88) 2.41 ± 1.32 (1.77 to 3.04) (− 1.63 to
0.58)
2.67 ± 1.68 (2.11 to 3.22)
SaO2 after 6MWD [%] 91.87 ± 4.63 (89.30 to
94.43)
(15) 91.71 ± 4.79 (89.24 to
94.17)
(17) (− 3.57 to
3.25)
91.78 ± 4.64 (90.10 to
93.45)
(32)
HR after 6MWD [/min] 99 ± 21.27 (88.07 to
109.93)
(17) 107 ± 19.64 (96.90 to
117.10)
(17) (− 6.30 to
22.30)
103 ± 20.56 (95.82 to
110.17)
(34)
Echocardiography at rest
Estimated sPAP [mmHg] 29.21 ± 5.16 (25.25 to
31.17)
28.58 ± 6.57 (26.04 to
31.43)
(− 4.52 to
3.26)
28.89 ± 5.83 (26.98 to
30.81)
RA area [cm2] 12.05 ± 4.24 (10.73 to
13.69)
11.68 ± 3.28 (10.45 to
13.66)
(− 2.86 to
2.13)
11.87 ± 3.74 (10.64 to
13.10)
RV area [cm2] 14.89 ± 4.56 (12.97 to
17.03)
14.13 ± 4.74 (12.65 to
16.82)
(− 3.82 to
2.30)
14.51 ± 4.60 (13.00–16.03)
TAPSE [cm] 2.50 ± 0.51 (2.23 to 2.71) 2.41 ± 0.33 (2.28 to 2.70) (− 0.37 to
0.20)
16,834 ±
0.43
(2.31 to 2.60)
Lung function
FVC [%] 69.17 ±
13.72
(62.56 to
75.78)
70.51 ±
17.61
(62.02 to
79.00)
(− 6.37 to
1.84)
69.84 ±
15.58
(64.72 to
74.96)
FEV1 [L] 2.40 ± 0.77 (2.03 to 2.77) 2.26 ± 0.63 (1.96 to 2.57) (− 0.60 to
0.33)
2.33 ± 0.70 (2.10 to 2.56)
FEV1% VC max [%] 79.31 ± 6.98 (75.95 to
82.68)
81.44 ±
15.38
(74.03 to
88.85)
(− 5.73 to
9.99)
80.38 ±
11.83
(76.49 to
84.27)
PEF [l/s] 5.46 ± 2.32 (4.34 to 6.58) 5.17 ± 1.72 (4.34 to 6.00) (− 1.63 to
1.06)
5.31 ± 2.02 (4.65 to 5.98)
TLC [l] 4.96 ± 1.07 (4.44 to 5.48) 5.08 ± 1.25 (4.48 to 5.69) (− 0.64 to
0.89)
5.02 ± 1.15 (4.64 to 5.40)
Residual volume [l] 1.94 ± 0.55 (1.68 to 2.21) 2.18 ± 0.70 (1.84 to 2.52) (− 0.18 to
0.65)
2.06 ± 0.63 (1.85 to 2.27)
DLCO [mmol/min/kPa] 5.28 ± 1.52 (4.55 to 6.02) 5.03 ± 1.33 (4.38 to 5.67) (− 1.20 to
0.68)
5.16 ± 1.42 (4.69 to 5.62)
DLCO % predicted 84.73 ± 2.61 (83.47 to
85.99)
84.16 ± 1.89 (83.25 to
85.08)
(− 2.07 to
0.93)
84.45 ± 2.27 (83.70 to
85.19)
SaO2 [%] 96.13 ± 1.80 (95.26 to
97.00)
96.82 ± 0.77 (96.45 to
97.17)
(− 0.23 to
1.60)
96.47 ± 1.41 (96.01 to
96.94)
PaO2 [mmHg] 78.78 ± 9.42 (74.24 to
83.32)
81.22 ± 5.91 (78.37 to
84.06)
(− 2.74 to
7.61)
80.00 ± 7.85 (77.42 to
82.58)
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Table 1 Demographic and clinical characteristics of the study population (Continued)
Parameter [unit] Placebo
(N = 19)
Ambrisentan
(N = 19)
Total
(N = 38)
Mean ± SD 95% CI n Mean ± SD 95% CI n 95% CI of
difference
Mean ± SD 95% CI n
PaCO2 [mmHg] 39.01 ± 3.63 (37.25 to
40.76)
37.23 ± 2.57 (35.99 to
38.47)
(− 3.85 to
0.29)
38.12 ± 3.23 (37.05 to
39.18)
Laboratory
Hemoglobin [g/dl] 13.54 ± 1.26 (12.93 to
14.14)
13.62 ± 1.13 (13.07 to
14.16)
(− 0.71 to
0.87)
13.58 ± 1.18 (13.19 to
13.96)
Hematocrit [l/l] 0.42 ± 0.03 (0.40 to 0.43) 0.41 ± 0.03 (0.40 to 0.43) (− 0.03 to
0.02)
0.41 ± 0.03 (0.40 to 0.42)
Platelet [100/nl] 2.53 ± 0.94 (2.08 to 2.98) 2.62 ± 0.63 (2.31 to 2.92) (− 0.44 to
0.61)
2.58 ± 0.79 (2.32 to 2.83)
Creatinine [mg/dl] 0.83 ± 0.16 (0.75 to 0.91) 0.86 ± 0.12 (0.80 to 0.92) (− 0.07 to
0.13)
0.85 ± 0.14 (0.80 to 0.89)
Potassium [mmol/l] 4.05 ± 0.38 (3.86 to 4.23) 4.20 ± 0.48 (3.97 to 4.43) (− 0.13 to
0.44)
4.12 ± 0.43 (3.98 to 4.27)
AST [U/l] 24.11 ±
21.78
(13.61 to
34.60)
19.79 ± 7.06 (16.39 to
23.19)
(− 14.97 to
6.34)
21.95 ±
16.12
(16.65 to
27.25)
ALT [U/l] 29.68 ±
24.93
(17.67 to
41.70)
24.68 ± 9.85 (19.93 to
29.43)
(− 17.47 to
7.47)
27.18 ±
18.87
(20.98 to
33.39)
LDH [U/l] 197.63 ±
54.74
(171.25 to
224.01)
197.53 ±
35.59
(180.37 to
214.68)
(− 30.48 to
30.27)
197.58 ±
45.54
(182.61 to
212.55)
CRP [mg/l] 5.18 ± 5.17 (2.69 to 7.68) 5.28 ± 11.60 (− 0.48 to
11.05)
(18) (− 5.84 to
6.04)
5.23 ± 8.77 (2.30 to 8.16) (37)
NTproBNP [pg/ml] 123.42 ±
142.96
(54.52 to
192.32)
267.83 ±
303.11
(117.10 to
418.57)
(18) (− 12.38 to
301.20)
193.68 ±
242.81
(112.71 to
274.63)
(37)
Quality of life SF-36
Physical functioning 50.26 ±
25.95
(37.75 to
62.77)
64.21 ±
25.83
(51.67 to
76.66)
(− 3.09 to
30.99)
57.24 ±
26.50
(48.52 to
65.95)
Physical role functioning 35.53 ±
40.24
(16.13 to
54.92)
51.32 ±
41.23
(31.45 to
79.19)
(− 11.01 to
42.59)
43.42 ±
40.97
(29.96 to
56.89)
Bodily pain 49.79 ±
28.96
(35.83 to
63.75)
62.00 ±
29.16
(47.95 to
76.05)
(− 6.91 to
31.33)
55.89 ±
29.33
(46.26 to
65.53)
General health perceptions 41.74 ±
13.07
(35.44 to
48.04)
54.42 ±
19.47
(45.03 to
63.81)
(1.72 to 23.65) 48.08 ±
17.58
(42.30 to
53.86)
Vitality 42.89 ±
19.32
(33.58 to
52.20)
50.53 ±
20.94
(40.03 to
60.62)
(− 5.62 to
20.89)
46.71 ±
20.24
(40.06 to
53.37)
Social role functioning 58.05 ±
25.99
(45.53 to
70.58)
74.47 ±
24.45
(62.69 to
86.26)
(− 0.18 to
33.03)
66.26 ±
26.24
(57.64 to
74.89)
Emotional role functioning 49.16 ±
46.33
(26.83 to
71.49)
63.16 ±
47.02
(40.50 to
85.82)
(− 16.71 to
44.71)
56.16 ±
46.58
(40.85 to
71.47)
Mental health 59.58 ±
18.85
(50.49 to
68.66)
64.42 ±
18.03
(55.73 to
73.11)
(− 7.30 to
16.98)
62.00 ±
18.36
(55.97 to
68.04)
Physical health score 43.89 ±
21.26
(33.65 to
54.14)
56.47 ±
23.87
(44.97 to
67.98)
(− 2.29 to
27.45)
50.18 ±
23.19
(42.56 to
57.81)
Mental health score 50.26 ±
20.70
(40.29 to
60.24)
61.42 ±
21.45
(51.08 to
71.76)
(− 2.71 to
25.03)
55.84 ±
21.55
(48.76 to
62.92)
SD standard deviation, HR heart rate, mRSS modified Rodnan Skin Score, WHO-FC World Health Organization functional class, CVP central venous
pressure, mPAP mean pulmonary arterial pressure, PAWP pulmonary capillary wedge pressure, CO cardiac output, CI cardiac index, SvO2 venous
oxygen saturation, PVR pulmonary vascular resistance, WU Wood Units, sPAP systolic pulmonary arterial pressure, RA right atrial, RV right ventricular,
TAPSE tricuspid annular plane systolic excursion, FVC forced vital capacity, FEV1 forced expiratory volume in first second, VC vital capacity, PEF peak
expiratory flow, TLC total lung capacity, DLCO diffusing capacity of the lung for carbon monoxide, SaO2 oxygen saturation, PaO2 partial pressure of
oxygen, PaCO2 partial pressure of carbon dioxide, AST aspartate-aminotransferase, ALT alanine-aminotransferase, LDH lactate dehydrogenase, CRP
C-reactive protein
In case of missing data, sample sizes are given in brackets
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Table 2 Changes of clinical parameters from baseline to 6 months
Parameter [unit] Placebo Ambrisentan 95% CI of
differenceChanges (n = 15) Changes (n = 17)
Baseline–6 months Baseline–6 months
Mean ± SD 95% CI n Mean ± SD 95% CI n
Hemodynamics at rest
CVP [mmHg] − 0.20 ± 2.76 (− 1.73 to 2.94) 0.82 ± 4.11 (− 1.29 to 2.94) (− 1.54 to 3.59)
mPAP [mmHg] − 0.73 ± 3.59 (− 2.72 to 1.26) − 1.00 ± 6.40 (− 4.29 to 2.29) (− 4.09 to 3.56)
PAWP [mmHg] 0.13 ± 3.20 (− 1.64 to 1.91) 1.24 ± 5.31 (− 1.50 to 3.97) (− 2.12 to 4.32)
CO [l/min] − 0.26 ± 1.11 (− 0.88 to 0.36) 0.58 ± 1.17 (− 0.03 to 1.18) (0.01 to 1.66)
CI [l/min/m2] − 0.31 ± 0.71 (− 0.71 to 0.08) 0.36 ± 0.66 (0.01 to 0.71) (16) (0.18 to 1.18)
SvO2 [%] − 3.48 ± 12.26 (− 10.89 to 3.93) (13)# − 2.79 ± 7.56 (− 7.60 to 2.01) (12)# (− 7.83 to 9.20)
PVR [WU] 0.02 ± 0.76 (− 0.48 to 0.43) − 0.59 ± 0.79 (− 1.05 to − 0.14) (− 1.25 to − 0.17)
Hemodynamics at peak exercise
mPAP [mmHg] 1.08 ± 7.39 (− 3.39 to 5.54) (13) − 0.73 ± 6.23 (− 4.18 to 2.71) (15) (− 7.10 to 3.48)
PAWP [mmHg] 0.85 ± 6.3 (− 2.96 to 4.65) (13) 4.93 ± 6.52 (1.16 to 8.69) (14) (− 1.01 to 9.17)
CO [l/min] − 0.05 ± 1.46 (− 0.94 to 0.83) (13) 1.24 ± 1.47 (0.43 to 2.05) (15) (0.15 to 2.44)
CI [l/min/m2] − 0.45 ± 1.36 (− 1.27 to 0.37) (13) 0.70 ± 0.81 (0.25 to 1.15) (15) (0.29 to 2.00)
SvO2 [%] − 28.35 ± 10.5 (− 35.41 to − 21.30) (11) − 30.05 ± 17.73 (− 42.73 to − 17.37) (10) (− 14.85 to 11.46)
Workload [Watt] 1.92 ± 16.01 (− 7.75 to 11.60) (13) 5.00 ± 16.9 (− 4.36 to 14.36) (15) (− 9.77 to 15.93)
HR max [b/min] 6.00 ± 18.74 (− 5.32 to 17.32) (13) 7.47 ± 12.01 (0.82 to 14.12) (15) (− 10.59 to 13.53)
PVR [WU] − 0.003 ± 0.34 (− 0.21 to 0.21) (13) − 0.84 ± 0.48 (− 1.12 to − 0.57) (14) (− 1.17 to − 0.51)
TPR [mmHg min L− 1] 0.16 ± 0.63 (− 0.22 to 0.54) (13) − 0.56 ± 0.48 (− 0.83 to − 0.29) (15) (− 1.16 to − 0.29)
6MWD
6MWD [m] − 16.53 ± 77.32 (− 59.35 to 26.29) 21.53 ± 34.6 (3.74 to 39.31) (− 4.30 to 80.43)
Borg dyspnea score 0.08 ± 1.54 (− 0.77 to 0.93) 0.62 ± 1.7 (− 0.25 to 1.50) (− 0.63 to 1.72)
SaO2 after 6MWD [%] 1.30 ± 5.1 (− 2.35 to 4.95) (10)# 2.07 ± 5.7 (− 1.22 to 5.37) (14) (− 3.92 to 5.46)
HR after 6MWD [/min] 6.83 ± 24.97 (− 9.04 to 22.70) (12)# − 1.53 ± 18.43 (− 11.74 to 8.68) (15) (− 25.56 to 8.83)
Quality of life SF-36
Physical functioning − 2.00 ± 25.20 (− 15.96 to 11.96) − 7.65 ± 21.66 (− 18.78 to 3.49) (− 22.56 to 11.27)
Physical role functioning 13.33 ± 38.81 (− 8.12 to 34.82) − 10.29 ± 42.44 (− 32.12–11.53) (− 53.14 to 5.88)
Bodily pain − 2.47 ± 28.19 (− 18.08 to 13.15) − 9.29 ± 23.87 (− 21.57 to 2.98) (− 25.62 to 11.97)
General health perceptions 0.20 ± 19.39 (− 10.54 to 10.94) − 2.71 ± 10.62 (− 8.17 to 2.75) (− 14.01 to 8.20)
Vitality − 5.00 ± 16.37 (− 14.06 to 4.06) − 3.53 ± 12.34 (− 9.88 to 2.82) (− 8.92 to 11.86)
Social role functioning 0.87 ± 27.69 (− 14.47 to 16.20) − 2.18 ± 19.21 (− 12.05 to 7.70) (− 20.08 to 13.99)
Emotional role functioning 8.80 ± 49.68 (− 18.71 to 36.31) − 9.82 ± 36.76 (− 28.73 to 9.08) (− 49.93 to 12.68)
Mental health − 3.73 ± 11.85 (− 10.30 to 2.83) − 4.47 ± 10.94 (− 10.10 to 1.16) (− 8.97 to 7.49)
Physical health score 0.87 ± 16.01 (− 8.00 to 9.73) − 6.71 ± 12.17 (− 12.97 to − 0.45) (− 17.77 to 2.62)
Mental health score 0.27 ± 19.77 (− 10.68 to 11.22) − 4.65 ± 9.47 (− 9.51 to 0.22) (− 15.89 to 6.06)
mRSS 0.73 ± 2.15 (− 0.46 to 1.93) 0.24 ± 0.97 (− 0.26 to 0.73) (− 1.68 to 0.68)
Lung function
FVC [%] − 1.04 ± 5.60 (− 4.15 to − 2.06) − 3. 31 ± 5.56 (− 6.27 to − 0.34) (16) (− 6.37 to 1.84)
FEV1 [L] − 0.06 ± 0.20 (− 0.17 to 0.05) − 0.11 ± 0.21 (− 0.22 to 0.01) (16) (− 0.20 to 0.11)
FEV1% VC max [%] − 0.67 ± 4.50 (− 3.16 to 1.82) − 4.17 ± 7.12 (− 7.97 to − 0.38) (16) (− 7.91 to 0.91)
PEF [l/s] −0.22 ± 1.76 (−1.12 to 0.76) 0.01 ± 1.15 (−0.61 to 0.62) (16) (−0.86 to 1.31)
TLC [l] − 0.03 ± 0.36 (− 0.23 to 0.17) − 0.06 ± 0.37 (− 0.26 to 0.14) (16) (− 0.30 to 0.24)
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Both PH patients in the ambrisentan group were cate-
gorized as newly developed manifest PH due to left heart
diseases characterized by an increased resting PAWP of
> 15mmHg (Fig. 2). One patient was a 71-year-old fe-
male with systemic arterial hypertension. Her resting
mPAP at baseline increased from 24 to 29 mmHg and
resting PAWP from 11 to 18mmHg after 6 months. Sub-
sequent examinations including left heart catheterization
showed a progression of left ventricular diastolic dysfunc-
tion. The second patient with manifest PH after 6months
was a 79-year-old female with a resting mPAP of 18mmHg
at baseline and a resting PAWP of 5mmHg, which mark-
edly increased to an mPAP of 36mmHg after 6months with
a resting PAWP of 22mmHg. Left heart catheterization re-
vealed a coronary artery disease.
The secondary endpoints CO and CI significantly in-
creased in the ambrisentan group compared to those in
the placebo group which tended to decrease, both at rest
(p = 0.047, p = 0.010, respectively) and at peak exercise
(p = 0.028, p = 0.015, respectively, Fig. 3). Furthermore,
change of TPR significantly differed between groups, with
a decrease of TPR in the ambrisentan group and an in-
crease in the placebo group (p = 0.022, Table 2). There
were no significant changes of PAWP in the ambrisentan
group compared to the placebo group at rest (p = 0.478) or
at maximal exercise (p = 0.111). Compared to the placebo
Table 2 Changes of clinical parameters from baseline to 6 months (Continued)
Parameter [unit] Placebo Ambrisentan 95% CI of
differenceChanges (n = 15) Changes (n = 17)
Baseline–6 months Baseline–6 months
Mean ± SD 95% CI n Mean ± SD 95% CI n
Residual volume [l] 0.05 ± 0.37 (− 0.16 to 0.25) − 0.03 ± 0.33 (− 0.20 to 0.15) (16) (− 0.33 to 1.83)
DLCO [mmol/min/kPa] − 0.45 ± 1.70 (− 1.48 to 0.57) (13) − 0.32 ± 1.44 (− 1.06 to 0.42) (− 1.04 to 1.30)
DLCO % predicted − 0.44 ± 1.84 (− 1.55 to 0.67) (13) 1.19 ± 1.81 (0.26 to 2.12) (17) (25.10 to 30.04)
SaO2 [%] 0.15 ± 1.86 (− 0.88 to 1.18) − 0.62 ± 1.50 (− 1.39 to 0.16) (− 1.99 to 0.44)
PaO2 [mmHg] 1.69 ± 9.95 (− 3.82 to 7.21) − 4.88 ± 7.60 (− 8.78 to − 0.97) (− 12.92 to − 0.22)
PaCO2 [mmHg] − 0.03 ± 2.63 (− 1.48 to 1.43) − 0.65 ± 2.77 (− 2.08 to 0.77) (− 2.58 to 1.33)
Echocardiography
Estimated sPAP [mmHg] − 0.93 ± 6.08 (− 4.30 to 2.43) − 0.82 ± 4.46 (− 3.11 to 1.47) (− 3.71 to 3.93)
RA area [cm2] − 0.47 ± 4.07 (− 2.72 to 1.79) 1.65 ± 2.67 (0.28 to 3.01) (− 0.34 to 4.57)
RV area [cm2] − 0.80 ± 3.05 (− 2.49 to 0.89) − 0.15 ± 3.46 (− 1.93 to 1.63) (− 1.72 to 3.02)
TAPSE [cm] − 0.19 ± 0.54 (− 0.49 to 0.11) 0.12 ± 0.41 (− 0.09 to 0.33) (− 0.04 to 0.65)
Laboratory
Hemoglobin [g/dl] 0.19 ± 0.68 (− 0.19 to 0.56) − 0.59 ± 0.86 (− 1.03 to − 0.15) (− 1.34 to − 0.21)
Hematocrit [l/l] 0.00 ± 0.02 (− 0.009 to 0.02) − 0.01 ± 0.02 (− 0.03 to − 0.0001) (− 0.03 to 0.00)
Platelets [100/nl] − 0.08 ± 0.39 (− 0.29 to 0.14) − 0.15 ± 0.37 (− 0.34 to 0.04) (− 0.35 to 0.20)
Creatinine [mg/dl] − 0.03 ± 0.09 (− 0.08 to 0.02) − 0.04 ± 0.11 (− 0.09 to 0.02) (− 0.08 to 0.07)
Potassium [mmol/l] 0.09 ± 0.40 (− 0.13 to 0.31) − 0.06 ± 0.62 (− 0.38 to 0.26) (− 0.53 to 0.24)
AST [U/l] − 4.40 ± 13.94 (− 12.12 to 3.32) 3.59 ± 7.96 (− 0.51 to 7.68) (− 0.08 to 16.06)
ALT [U/l] − 4.93 ± 15.01 (− 13.25 to 3.38) 5.12 ± 7.83 (1.09 to 9.15) (1.56 to 18.55)
LDH [U/l] − 7.00 ± 27.36 (− 22.15 to 8.15) 2.82 ± 29.57 (− 12.38 to 18.03) (− 10.84 to 30.49)
CK [U/l] 9.21 ± 40.50 (− 14.17 to 32.60) (14) 5.53 ± 36.80 (− 13.39 to 24.45) (− 32.10 to 24.73)
CRP [mg/l] − 1.08 ± 3.52 (− 3.03 to 0.87) − 2.71 ± 12.17 (− 8.97 to 3.54) (− 8.29 to 5.03)
NTproBNP [pg/ml] 31.00 ± 85.83 (− 20.87 to 82.87) (13) − 15.63 ± 207.48 (− 126.18 to 94.93) (16) (− 172.95 to 79.70)
SD standard deviation, CVP central venous pressure, mPAP mean pulmonary arterial pressure, PAWP pulmonary capillary wedge pressure, CO cardiac output, CI
cardiac index, SvO2 venous oxygen saturation, PVR pulmonary vascular resistance, WU Wood Units, HR heart rate, b beats, min minute, TPR total pulmonary
resistance, 6MWD Six-minute walking distance, SaO2 oxygen saturation, HR heart rate, mRSS modified Rodnan Skin Score, FVC forced vital capacity, FEV1 forced
expiratory volume in first second, VC vital capacity, PEF peak expiratory flow, TLC total lung capacity, DLCO diffusing capacity of the lung for carbon monoxide,
SaO2 oxygen saturation, PaO2 partial pressure of oxygen, PaCO2 partial pressure of carbon dioxide, sPAP systolic pulmonary arterial pressure, RA right atrial, RV
right ventricular, TAPSE tricuspid annular plane systolic excursion, AST aspartate-aminotransferase, ALT alanine-aminotransferase, LDH lactate dehydrogenase, CK
creatine kinase, CRP C-reactive protein, NTproBNP N-terminal pro-brain natriuretic peptide
In case of missing data, sample sizes are given in brackets
#Values with more than 20% missing data
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group, PVR in the ambrisentan group significantly de-
creased over 6months both at rest (Fig. 4) and at maximal
exercise (p = 0.012, p < 0.0001, respectively). There was no
significant difference in mPAP (p = 0.494), workload, and
heart rate at peak exercise between the two groups.
WHO functional class, 6-min walking test, quality of life,
and skin fibrosis (Table 2)
At 6months, 17 patients (100%) in the ambrisentan
group and 13 patients (86.7%) in the placebo group were
in WHO-FC II. The remaining 2 patients in the placebo
group were in WHO-FC III.
After 6 months, the mean 6MWD improved by 21.53
m in the ambrisentan group and decreased by 16.53 m
in the placebo group (p = 0.095; Table 2). No differences
were detected regarding quality of life and skin fibrosis.
Sensitivity analysis of patients with dcSSc did not reveal
different results.
Lung function, transthoracic echocardiography, and
laboratory data (Table 2)
The changes in predicted DLCO showed a decrease in
the placebo group and an increase in the ambrisentan
Fig. 2 Changes of mPAP over 6 months. No patients at baseline had a resting mPAP of ≥ 25 mmHg. After 6 months, 2 patients in the
ambrisentan group developed a resting mPAP of > 25 mmHg. The dotted line indicates a resting mPAP of 25mmHg. *: Two patients in the
ambrisentan group had a resting PAWP of > 15 mmHg after 6 months; they were reclassified as PH due to left heart disease. #: Three patients in
the placebo group developed a resting mPAP of ≥ 25mmHg at month 6 with a resting PAWP of ≤ 15 mmHg; thus, they were diagnosed as
having SSc-APAH after 6 months. The mean change of resting mPAP over 6 months in the ambrisentan group was − 1 ± 6.4 mmHg, and that in
the placebo group was − 0.73 ± 3.59 mmHg. The changes between the two groups were not significantly different (p = 0.884). Ambrisentan did
not significantly decrease the mPAP at rest over 6 months compared to placebo
Fig. 3 Changes of peak CI over 6 months. The mean change of CI at maximal exercise over 6 months in the ambrisentan group was 0.70 ± 0.81 L/
min/m2 and that in the placebo group was − 0.45 ± 1.36 L/min/m2. Ambrisentan significantly increased the CI at maximal exercise over 6 months
compared to placebo (p = 0.015)
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group (95% confidence interval of the difference 0.25–
3.0%, Table 2). No changes between the two groups were
recorded with regard to other parameters of pulmonary
function. A change in the partial pressure of oxygen
(PaO2) was recorded, with a decrease in the ambrisentan
group, whereas it slightly increased in the placebo group.
Parameters of right heart size and function did not
show differences between groups.
Patients receiving ambrisentan had a not clinically
relevant drop in hemoglobin concentration (− 0.59 ±
0.86 g/dl, 95% confidence interval − 1.03 to − 0.15)
compared to placebo. No differences were identified
regarding other laboratory parameters, including
those concerning renal failure, liver damage, and
NTproBNP levels.
Safety and tolerability (Table 3)
Most of the adverse events were of mild or moderate in-
tensity in both groups and are summarized in Table 3.
Serious adverse events were more frequently reported for
the placebo group (Table 3), with all events requiring
hospitalization, but being resolved at the end of the study.
Discussion
To the best of our knowledge, EDITA is the first ran-
domized, controlled study to assess the safety and effi-
cacy of an early treatment with a PAH-targeted drug in
patients with SSc and mildly elevated mPAP (mPAP 21–
24mmHg) and/or exercise PH in comparison with pla-
cebo. Patients did not significantly differ in the primary
endpoint change of mPAP during the study. However,
the secondary hemodynamic endpoints as peak TPR as
well as right heart function (CO, CI), and PVR signifi-
cantly improved in the ambrisentan group, both at rest
and at peak exercise compared to placebo. No patients
in the ambrisentan group but three patients from the
placebo group progressed to SSc-associated PAH within
6 months of treatment (although for two patients the
progression was only minimal). Ambrisentan was well
tolerated, with a favorable safety profile.
Fig. 4 Changes of PVR at rest over 6 months. Ambrisentan patients had on average a lower PVR at 6 months compared to placebo. The mean
change of PVR at rest over 6 months in the ambrisentan group was − 0.70 ± 0.78 WU and that in the placebo group was 0.01 ± 0.71 WU.
Ambrisentan significantly decreased the PVR at rest over 6 months compared to placebo (p = 0.012)
Table 3 Adverse events
Event Placebo
(N = 19)
Ambrisentan
(N = 19)
Number of patients (percent)
Patient with at least 1 adverse event 17 (89.5) 17 (89.5)
Headache 6 (31.58) 6 (31.58)
Edema 4 (21.05) 8 (42.11)
Dizziness 6 (31.58) 0 (0)†
Diarrhea 2 (10.53) 4 (21.05)
Nausea 3 (15.79) 2 (10.53)
Paresthesia 0 (0) 4 (21.05)
Coronary artery disease 3 (15.79) 1 (5.26)
Hypotension 2 (10.53) 2 (10.53)
Epistaxis 1 (5.26) 3 (15.79)
Serious adverse events*
Lower jaw fracture 0 1
Angina Pectoris 1 0
Coronary artery disease 1 0
Gastrointestinal infection 1 0
Lymphangitis 1 0
Raynaud 1 0
The adverse events listed here are those that occurred in at least 10% of
patients (total) during the course of the study
†Statistically significant at level 0.05
*All serious adverse events fulfilled the criterion of hospitalization
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Effects of ambrisentan in patients with SSc and early
pulmonary vasculopathy
While the primary endpoint of the study was not met,
parameters of right ventricular (RV) function and PVR
at rest and during exercise showed significant improve-
ments during the study. Data from large registries have
already shown the prognostic importance of CO, CI, and
PVR at rest [25, 26]. These three parameters showed a
significant improvement in the ambrisentan group after
6 months in our study, compared to placebo.
Besides resting values, exercise hemodynamics are able
to unmask early RV dysfunction and vascular remodel-
ing, especially in patients with SSc and mildly elevated
mPAP, who usually display normal right heart function
at rest [9, 27]. In our study, improvements of CO and CI
at peak exercise were even more pronounced than
changes observed at rest. The increase of CO and CI
during exercise (also called RV output reserve) is able to
provide useful information regarding prognosis of pa-
tients with pulmonary vascular diseases [28, 29].
The finding that change of TPR slope significantly
differed between groups and that only patients in the
placebo group presented with a manifest SSc-APAH
during follow-up, whereas two patients in the ambrisen-
tan group developed left heart disease PH, may be a hint
for the beneficial effect of ambrisentan on the pulmon-
ary vasculature, though the primary endpoint of mPAP
change was not met. As two patients in the intervention
group presented with left heart disease PH at the end of
the study, though they did not present with significant
left heart disease at baseline, treatment with ambrisentan
may potentially lead to the unmasking and progression
of left heart disease in patients with SSc [30]. Further-
more, pulmonary fibrosis has to be taken into account
when initiating treatment with ambrisentan, as ambri-
sentan may lead to worsening of PaO2 [30], as found in
our cohort, though not clinically relevant. Patients who
are eligible for an early treatment with PAH-targeted
drugs have therefore to be carefully selected. Further-
more, hemoglobin as well as hepatic values have to be
thoroughly monitored. Further, larger-scaled studies are
needed to investigate the effect of early PAH-targeted
treatment in SSc patients with mildly elevated mPAP
and/or exercise PH and its impact on the pulmonary
vascular system and right heart function.
Comparison with previous reports on treatment with
PAH-targeted drugs in patients with SSc and early
pulmonary vasculopathy
Two uncontrolled small open-label reports were previ-
ously performed, one with ambrisentan [15] and one
with bosentan [16]. Our data are in line with those
published by Saggar et al. on 12 patients with exercise
induced PH < 25mmHg at rest and > 30 mmHg at peak
exercise receiving ambrisentan treatment for 24 weeks.
After 24 weeks of treatment, the authors did not find a
significant decrease of resting mPAP (p = 0.65) but a re-
markable improvement of CO at rest and during exer-
cise (p = 0.01 and p = 0.006 respectively) and of PVR
during exercise (p = 0.003).
Kovacs et al. assessed in a retrospective uncontrolled
study 10 patients with mildly elevated mPAP (21–24
mmHg) receiving bosentan for 24 weeks. Apart from an
improvement in right heart function (CO at rest p = 0.05),
they reported a significant reduction of mPAP at rest and
peak exercise (p = 0.03 and p = 0.02, respectively) after 24
weeks of bosentan treatment [16]. Congruently with the
results of Kovacs and Saggar, we did not find significant
improvements in 6MWD, QoL, and WHO-FC. Since
more than 70% of our cohort had 6MWD > 400m and
WHO-FC II at baseline, our findings are concordant with
the results of a post hoc analysis of the ambrisentan in
PAH, randomized, double-blind, placebo-controlled, mul-
ticenter efficacy study 1 and 2 (ARIES)-1 and ARIES-2
studies, which reported that ambrisentan had a greater
effect on 6MWD and WHO-FC in patients with more
severe PAH [31].
Clinical implication and safety
Pulmonary vascular abnormalities in PVR have been
shown to be already remarkable even in patients with
only mild symptoms [32] and may precede an overt
disease [33]. The improvement in PVR observed in our
cohort might indicate that active treatment with ambri-
sentan is able to prevent the progressive vascular remod-
eling in SSc patients with an early form of pulmonary
vasculopathy.
Ambrisentan treatment has shown a good safety pro-
file, which is in line with the current analysis of safety
and tolerability [34, 35]. Undesirable effects of ambrisen-
tan recorded in our study were a clinically not relevant
drop of hemoglobin concentration and PaO2. The reduc-
tion of hemoglobin found in our study may be due to a
class effect of all endothelin receptor antagonists, and
the most probable cause might be fluid retention [36]. A
non-dose-dependent change in hemoglobin values was
also found in the first 12 weeks of the ARIES-1 and
ARIES-2 studies, with stabilization during the subse-
quent 24 weeks [11]. Long-term extension of the ARIES
studies confirmed that hemoglobin levels tended to
stabilize over time [37].
Limitations
Our study may have been biased due to the inclusion
criteria of including patients with mildly elevated mPAP
both at rest and during exercise. The distribution of
these entities may have influenced the results, though it
did not differ between the two groups. As there is
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growing evidence that both states with mildly elevated
pressures at rest as well as during exercise bear the risk
of developing manifest pulmonary vascular disease, we
included both phenotypes into the study. Furthermore, a
longer study period of more than 6months may have
helped to interpret the results, as longer time intervals
could have led to more distinct changes in pulmonary
hemodynamics. As two patients of the placebo group
with manifest PAH at follow-up increased only minimal,
the changes are too small to draw definite conclusions.
Larger-scaled studies with longer observation periods
are needed to further investigate this issue.
Among our study cohort, two patients developed left
heart disease PH during the study period, which was based
on PAWP at rest and during exercise. While it would be
preferable to clearly distinguish the effects of targeted
treatment on the pulmonary vasculature, it is hardly
possible to exclude interfering diseases such as left heart
and lung disease. Patients in our study were only enrolled
in the absence of significant left heart or lung disease at
baseline to limit determining factors of mPAP elevation
and development of manifest PH. To further characterize
patients with PH due to left heart disease, the assessment
of the diastolic pressure gradient and echocardiographic
parameters of diastolic dysfunction would have been de-
sirable. The higher frequency of patients with lcSSc and
shorter duration of SSc in the ambrisentan group may
have influenced the results, though sensitivity analysis of
patients with dcSSc did not show different results.
“Development of PAH” as a primary endpoint would have
required a large sample size, which would not have been
feasible in a single-center study.
Conclusions
Although the primary endpoint was not met (change
in mPAP over 6 months), ambrisentan was associated
with significant improvements of secondary endpoints,
such as peak TPR, PVR, CO, and CI both at rest and
at peak exercise. Ambrisentan showed good safety
and tolerability in this patient cohort. The potential
risks of ambrisentan of unmasking left heart disease,
drop of hemoglobin, and PaO2 have to be taken into
account before treatment initiation and thoroughly
monitored during treatment. All SSc patients included
in this study had symptoms such as shortness of
breath with a WHO-FC II-III, some of them revealed
already an impaired RV function at rest and during
exercise. Thus, these patients had already a cardio-
pulmonary disease and further treatment studies are
mandatory. Determinants of treatment response as
well as development of comorbidities should also be a
focus of future studies. The results of this study will
be helpful to design future trials.
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